Your browser is old and is not supported. Upgrade for better security.
Wefunder logo

JustLight pbc

Breakthrough Technology to Reverse Alzheimer's Disease without Side Effects

Follow JustLight pbc to be notified if they later decide to raise funding.


🌻 Sunflower Rx™ is shown to reverse cognitive decline for Dementia patients measured by ADAS-cog.
💸 $2.9M+ Invested | Fortune 500 Japanese Corporation, Asahi Kasei | Primary investment partner.
📈 Fully functional Sunflower™ device mass-manufactured | Gen 2 Sunflower Rx™ in pre-production.
✔️ Photobiomodulation is a safe & effective treatment for neurodegenerative diseases.
🏆 FDA Presubmission complete for Alzheimer’s treatment | Partnered with top Clinical Research Org.
📱 Sunflower Rx™ App makes treatment easy to provide at home.
🔥 Solving the $321B Alzheimer's crisis with the first safe & effective device approved by the FDA.

Our Team

Photobiomodulation is already clinically shown to be a safe and effective treatment for Alzheimer's - yet the technology is not currently applied at scale. I founded JustLight to revolutionize healthcare through universal access to photobiomodulation. Soon, photobiomodulation will be the standard of care for degenerative diseases.

Alzheimer’s Treatment with Photobiomodulation

Alzheimer's Disease in the USA

Alzheimer's is the most common type of dementia, a general term for memory loss and other cognitive impairments serious enough to interfere with daily life. Alzheimer's disease accounts for 60-80% of dementia cases.

6,000,000 Americans - More than 6 million Americans are living with Alzheimer's disease. By 2050, this number is expected to reach 13 million.

1 in 3 Senior Deaths - A third of seniors will die with Alzheimer's or another dementia. It kills more than breast cancer and prostate cancer combined.

$321 Billion in 2021 - The cost of Alzheimer's in America is expected to surpass $1 trillion by 2050.

Why JustLight?

JustLight is developing the first FDA-approved, safe and effective treatment for Alzheimer’s disease. We aim to solve the $321 billion Alzheimer’s crisis and revolutionize our healthcare system through universal access to Photobiomodulation.

Our patent-pending technology automatically adjusts the LED Light output to replicate clinical parameters, delivering precise and effective photobiomodulation treatment in the comfort of home. 

What is Photobiomodulation?

Photobiomodulation, or PBM, uses specific wavelengths of light to safely energize and support the cells in our bodies. PBM has three primary mechanisms that contribute to reversing degenerative decline.

Reduces Inflammation: “One of the most reproducible effects of PBM is an overall reduction in inflammation, which is particularly important for disorders of the joints, traumatic injuries, lung disorders, and in the brain.” [a]

Increases Blood Flow:
“Near-infrared PBM was found to induce a 27% increase in microcirculatory flow that increased to 54% during the 20-minute follow-up period (P = 0.049 and P = 0.004, respectively), but red light PBM did not increase the median flow” [b]

Increases Cellular Energy: “Intracellular ATP levels show a biphasic increase with 660 nm and 810 nm, but a dose dependent decrease with 415 nm and 540 nm” [c]

Neurodegenerative Intervention Comparison

While drugs aim to slow neurodegenerative decline, Photobiomodulation is shown to reverse decline and improve brain function over time.

Sunflower Rx™

Sunflower Rx™ aims to be the world's first FDA-approved safe and effective Alzheimer's medical device.  Sunflower Rx™ is making Alzheimer's treatments and Photobiomodulation understandable, accessible, and enjoyable.

With the tap of your phone, Sunflower Rx™ delivers a precise blend of red & infrared light to the brain to support cell recovery. The flexible stem allows simple positioning 

- Initial pilot study data of Sunflower Rx™ shows memory recall improvement of dementia patients measured by ADAS-Cog scores.

- Sunflower Rx™ only utilizes safe wavelengths of light and does not have negative side effects. 

- The Clinical Research Organization Amarex has provided a detailed roadmap for Sunflower Rx™ FDA approval of Alzheimer’s Disease with an FDA Presubmission meeting on June 13th, 2022.

- The Sunflower Rx™ App provides clinically-informed doses of specific wavelengths of light for best results. 

The Sunflower Rx™ App

The Sunflower Rx™ App is rooted in science, automatically adjusting the intensity and wavelength of Photobiomodulation treatments based on current clinical insights. The simple controls eliminate the need for a trained medical professional to administer this therapy. The Sunflower Rx™ App truly puts health in your hands and allows for at-home treatments. 

Market Opportunity

Photobiomodulation and Sunflower Rx™ will disrupt the $321B US Alzheimer’s market.

JustLight has designed key Intellectual Property to protect and optimize Photobiomodulation treatments for Alzheimer's Disease. A full intellectual property report JustLight is available upon request.


Ted used Sunflower Rx™ on his father, an 89-year-old man living with dementia.

After just a few weeks of treatments, Ted's father had unprecedented improvements in cognition, attention, and most notably, memory. Below is a quote from an interview with Ted; you can watch the full interview by clicking the link at the bottom of this page.  

Below is a visual representation of Ted's father's improvement in cognition and memory using the clock-drawing test.

The clock-drawing test is a quick way to test and monitor dementia, including Alzheimer's disease. It involves drawing a clock on a piece of paper with numbers, clock hands, and a specific time. The inability to do so is a strong indication of mental decline.

Notice how the first drawing shows a backwards clock with the hands and numbers in the wrong places. The second drawing was taken after 36 days of treatment; notice how much more accurate this drawing is than the original. 


Photobiomodulation provides a superior alternative to pharmaceutical intervention; a safe, effective, and enjoyable therapeutic for dementia that will improve healthcare forever.

Drugs that aim to slow neurodegenerative decline are not our competition. Photobiomodulation will make these drugs obsolete. 

However, we'll be the first to admit that we're not the only one going after an FDA approval for a Photobiomodulation device to treat Alzheimer's. Due to the unprecedented results of PBM on brain health; we're actually surprised there isn't more competition yet.

Unfortunately, the current photobiomodulation devices are not friendly, familiar, or designed with dementia patients in mind. Below is a selection of the clinical devices that have demonstrated great results, but have failed to gain mainstream adoption.

The Path to an FDA Approval

We have partnered with Amarex, a world-class clinical research organization, to develop our pathway to FDA Approval for Alzheimer's Disease with Sunflower Rx™.

The FDA has three major criteria for Approval:

Photobiomodulation is already recognized as 'low-risk' by the FDA. This allows JustLight to skip the phase one clinical analysis for safety, saving millions of dollars and years of review.

Photobiomodulation has been clinically demonstrated to improve cognitive function, cerebral blood flow, memory recall, and standardized test scoring. You can learn more from the systematic clinical review: Photobiomodulation for Alzheimer's Disease; Has the Light Dawned?

Unmet Need: Alzheimer's Disease has over 6 million individuals suffering and the number grows every year. The FDA weighs the unmet need of a disease heavily when awarding approval for a drug or therapeutic. 

Investment Roadmap

To date, we have raised over $2.6 million with a primary investment partner Asahi Kasei, the Fortune 500 Japanese conglomerate and world leader in LED manufacturing.

We are now actively raising a Series A investment of $25million to expedite our pathway to FDA Approval for Alzheimer's Disease with Sunflower Rx™.

We've opened up a portion of this Series A investment round through WeFunder to allow safe and secure investments from anyone passionate about ending Alzheimer's Disease.

At a bird's eye view, we will use our Series A investment to continue to drive forward with our clinical trials and FDA approval, to make key hires, to give us the funds to continue to file systematic patents within the PBM/Alzheimer's space and to continue building out our DABISO self-optimization software to maximize the results and benefits of Photobiomodulation.

Join us as we revolutionize healthcare through universal access to Photobiomodulation. 🌻

Thank you!